Insulet (PODD) 2 Nov 232023 Q3 Earnings call transcript

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Third Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations.

Thank you. Good afternoon and thank you for joining us for Insulet's Third Quarter 2023 Earnings Call. With me today are Jim Hollingshead, President and Chief Executive Officer; and Lauren Budden, our Interim Chief Financial Officer and Treasurer. Both the replay of this call and the press release discussing our quarterly results and our guidance will be available on the Investor Relations section of our website. is quarter website earnings our on our supplemental third presentation. Also document you updates. summary to encourage for reference business We and that a metrics of key

such we inherent expectations. call SEC to detailed may also that financial forward-looking inform in statements. We'll and Insulet like our differ we filings limitations to be the statements explanation measures operating performance, interested assessing from the namely period materially current of adjusted adjusted operating statements during our this made a by refer parties we believe non-GAAP operating of Before you what respect of other course period. of could management begin, Please helpful the constant gross would revenue for our performance discuss certain with from the with align and to currency cautionary is revenue, performance, investors, effect and growth, uses measures excluding analysts are and margins, which as they as in and measures to to of These exchange. measures foreign EBITDA supplemental our

unless on basis. With the commentary over growth and which be to be changes will of constant year-over-year reported regarding a turn the rates, stated, financial year-over-year Additionally, percentage on revenue basis will dollar that, with all I'll currency a otherwise exception Jim. call

our developments our Good financial dedication execution, provide track and of review team's want many discuss achievement XXXX we access afternoon joining clinical today's us. Thanks I for do growth to rapid X an our continuing results in significant key and in complete QX market focus, our and momentum. On you global market and to enter Deb. pipeline. and Thanks, and for progress work, transformational are traction, innovation quarter strategic with thank update with on year was another another things: call, Insulet strong and to on milestones.

with XX%. exceeded our third revenue of of growth expectations XX%, including total U.S. growth Our Omnipod quarter over

results, remarkable the of These total of context year achieved growth company especially We our coming strong XX%. are also comparables. prior in

use, AID full we access early innings. QX X Its success X, year. Performance it result, system. our a the huge of people launch to is primarily impact again platform. diabetes, made management. as our simplify U.S. and driven only on continues anniversary the for affordable It X it diabetes lives of insulin in the continues the is the the real-world is Omnipod pod-based AID and and to of see was As revolutionary Omnipod improve and X automated outcomes X improved the the having system, represented Omnipod transform delivery Omnipod widespread by FDA-cleared, with fully raised the guidance of offering market. to have and ease simplicity, are gratifying disposable, positive the we leading Omnipod once only of

With pharmacy access, it an the prescribe, care added and efficient and channel simple U.S. pay-as-you-go practitioners, X technology. onboarding makes health conveniently our and payers easy model patients of breakthrough and afford access to benefits pathway, Omnipod for

U.K. XX% sign this in diabetes transform customer Omnipod the starts. new U.K., of In our are of new X we a revenue in June. starting in Omnipod adoption. XX% our under to the accelerated are strong past very X taking care. growth in driving early markets, of global almost We QX, starts drove power X the customer approximately growth global X the to rollout belts and sequential It's year-over-year strong international beginning with With U.K., now seeing quarter full early Omnipod also the

leader, will new pumps the an with results, is split, in that specifically emerge everywhere percentage on driving Omnipod the X and success our QX, Omnipod XX-XX also tubed available. The coming historical is mix. Omnipod was age Omnipod Omnipod we across We confident market-leading Based multiple During Germany exciting. August, of which momentum it MDI in as in is markets X from we expected, rollout as as and X into these of legacy market these estimated the X commenced for early bringing daily globally. on growing are type In from customer MDI. Omnipod estimate In groups starts the customer customer and new positioning of quarter remains U.S. penetration the all X that in injections was pump also X majority led and our share, we to the designed outstanding Insulet are represent individuals in continue to and another we the line QX, starts retention the type markets. QX, leader both vast and the in new starts U.S., in U.S. a customer strong. in of both while are our offer clear customers

up a and In In In among in HCPs addition of prescription to XX,XXX there of appeal are this we and Omnipod high growing of writing Omnipod of broad to for X,XXX endocrinologists, a it. QX, product patients, QX. from another number market scripts over XX,XXX, the awareness ease to demand X. X,XXX are increase growing in growing over where prescribers, shows saw

see years, Omnipod a for great the many Importantly, amongst our amongst the patients this X's scripts hallmark who clinics and HCPs appeal is evidenced demand Podders also growing system. loyalty pump the extensive been number write pump-prescribing the reach is historically of these our that is and seen that growing broad the at to prescribing high-volume market. Omnipod by it confidence are critical not defines to brand access HCPs. of has for

In number fact, tell the that when an choice, overwhelmingly patients us increasing their Omnipod. given choose

in reach at type we'll type diabetes be indication as insulin a with insulin need for In therapy be products population. Omnipod our in offer people adoption who customer of strengthen X continued care. part XX% new Omnipod leading in steady that X starts. of their X X the with demonstrating new market. the continues benefits come starts the across an offer the patients our products, quarter, to the Omnipod use results type approximately portfolio customer These pump Our clear also able to pace from that U.S. X market type with representing QX our DASH of of the our millions the type conviction a

While in have X we pivotal AID to we our obvious for in an this type to indication for encouraging. market U.S. look X to forward end, Omnipod existing is trial and can't bringing X market these extension customers our goal we secure to the that X type announce very to our pivotal enrollment that reached for X, study. the Omnipod week we underlying yet excited And demand type use. And our are once complete we

confidence participants X comparing Omnipod previous be X HCPs XX-week up protocol reminder, participants Omnipod big will insulin. to require and a to strengthens who therapy. type population in a continues with a The feedback As this patients participants' of strong have impact a X XXX from is study the of study that our critically very to and underserved

updates impact further about like of will to our trial GLP-Xs few a on provide We the comments debate about markets. make as progresses. I'd the the ongoing

conclusions. type to the for slide is we apparent in there diabetes. Last published and X X we going recently help slides several clear, them presented alter large upon do issues autoimmune apparent mechanism to They published GLP-X an with many type GLP-X retrospective at materially important we and the that for as indicated help, we of same that regard use made patients there which believe type of users have their of presented X diabetes class end was no years. suggests short disorder, impact semaglutide, and is markets. indicated in presentation X underlying an week, into our not a This X drugs drugs of X for the beta EASD. course mechanism a These decline impact of more as diabetes, In for these in innovation been to of applaud GLP-Xs they type the drugs cell we we've condition. not As data is diabetes, to study a for XX,XXX aim innovation. Further, the for characteristic an update are no those month, evidence type we of Likewise, as based is detail. reminder, use a people progression important

liraglutide AXc duration First, has glycemic in identical of on magnitude semaglutide control of as and terms almost reduction. impact the

shows between only the and benefit more adherent the clinical controlled control, most users level that demonstrated receive adherence real-world settings. dose such Second, of evidence glycemic relationship this clear very in that a has been

continue weight with and to persistence effect X demonstrated continues Finally loss importantly, no of for independent be their short, limited to semaglutide or incremental have progress semaglutide even real-world and of diabetes weight control. In drugs, to weight study diabetes this that type loss. and loss progress previous using duration over the users patients glycemic was evidence shows with of in

insulin need on available our Because you condition disease need progress, incorporate into more in data interested are positioned well in they therapy. continues our eventually their progress which customers to who to their page. These detail, people those underlying Insulet Insulet as these updated will first to existing intensive to insulin treatment. refer is presentation, type into with we most reinforce Investor view. the add to is and For diabetes and X their then basal serve incredibly the

type have winning people strong already continue population. underserved we represent with a are in market, that X We and and conviction large to this diabetes

to GO, We delivery come and portfolio power which a in Omnipod options, efforts Omnipod insulin the full broad our Omnipod are few will DASH, moments. continuing of a including to back bring of X I

pivotal X we are several progressing type In addition clinical trial, to initiatives. our additional

our to controlled to the Omnipod We using last process trial the Omnipod have expect are X systems. and in show of over completed GX. clear the non-AID the with analyzing with the which benefits therapy participant we preparing of randomized pleased data, X We're protocol in Dexcom's

in study, we remarked Libre progress ease September. have also are simplicity for MDI with for is great tubed due began enrollment X our including and making the in of RADIANT outpatient occur X transition therapy for users norm often is integration for in trial, which to to in the where Clinicians complexity about the the which pump existing the offerings. of hospital it Omnipod the to days regions AID setting, We

market to participants the we excited of Omnipod that areas the driving Abbott's key choice the system. our platform, program. version to aim provide to the of ways with makes offering is pricing achieve international market innovation X customer on In easy these studies with X to Both context, our and that The where sensor X of of promise to product. Libre and excited initiatives with in will algorithm to is upstream have has GO, is markets. I'd requested XXX(k) for the our minimum moving the is X advanced of advanced We use. In using FDA that Omnipod to forget the Omnipod Insulet, current platform, of in evidence for features some integration order us: from our for type X Omnipod CGM widespread now our for are viable drive point we the our we like expanding received the future iOS it full are to X app. This turn milestone most our another need of launch Omnipod and AID study as phone across the are customers. our and success one for both for clearance innovation control major expand the iOS access

in We are our a upon new have the the limited X as Omnipod customer of for progress early platform, our iOS U.S. and a our integrations Because to regard expect our the completion, represents as expand CGM, Dexcom to to as thrilled I've to market And X our already iOS Omnipod make sensor Abbott, well release XXXX. mentioned our will to provide available completely existing to successful the to in Libre progress. iOS partners, begin steadily future app with with possible. With broadly efforts soon base we software customers. integration context we option trial. as European opportunity sensor continue

small are with in to be is and And release X work confident market-leading integration Dexcom's excited GX early these we sensor, innovations, therapy of at innovation upstream meaningfully coming into contribute maintain will hard who diabetes offer. is us we effort insulin Omnipod their Omnipod are for limited for our plus that also designed long-term moves X extend Even are we trajectory. people a which GX XXXX. type to GO, key start AID to that radically insulin progresses. as will Omnipod the to to We our with to we announce able are also leadership. A is market simplify the initiation need market this growth planning X complete basal that and penetration from of

whom who We are don't Omnipod physicians. who have commercial commenced most are U.S., on for GO HCPs the new the which Omnipod, pilot primary in of call to that typically includes we care

all us present to commercial is PCPs GO educate on the also offerings. to and Our our with Omnipod pilot providing of opportunity Omnipod

us therapy our pump therapy. is are Although much that telling PCPs pilot, than early in easier Pod

learn portfolio. As entire about these a result, Omnipod want the to HCPs

We to will expect for our help Learnings pathway both make commercial pilot plans our Omnipod from GO these and type easier commercialization far X treatment us for GO Omnipod ongoing in refine XXXX. to the patients. DASH Omnipod

is Evolution enhancements We our simplicity earlier to on further to we feasibility are order being our algorithm in Omnipod of New algorithm our is data which cycle both this with of our feasibility able Omnipod year study been effective the from the population continuing algorithm users. ability to X the We've began use. actual progress in entire Omnipod X the of because to is to next-generation work the AID life the and essentially of launch AID because gather The drive goal of specifically because of Zealand. of test highly on-market aspects potential very this trial, early offerings conducted in which and unique X, in study to usage

cloud time. capabilities, allow will connectivity us of to -- development that data over with coupled expect our accelerate our Omnipod algorithm for efforts sciences X, materially We

from succeed information to In on motion, any and relying products, strong or confident our information. clear developing have designed, resources for disclosing secrets. The years trade misappropriation" its update enabling and in suit we affiliated manufacturing, granted important intellectual obtaining against Insulet's selling August, our on a U.S. or after a EOFlow property manufactured evidence, any other which continued to indeed, third-party "that injunction lead derives scalability. likely from proprietary of to against in In asset is growth. we of technically EOFlow evidence incorporates that key month, that Last found of considerable EOFlow which confidential customer invested or and product secrets of and Insulet portfolio, secrets. using our initial or an to the from many stop court Finally, we EOFlow, are a preliminary merits prohibits claim." We developed relief parties new the requesting misappropriation granting Insulet's have extended trade the marketing trade injunction contains, also prior on restrain substantial, the is filed we preliminary terms the court some the request Insulet's any over court issue a our Omnipod "very Insulet's and to

protect continue to business. another those sustained defend vigorously outstanding we will IP we investments. In closing, quarter, completed to We our have and our momentum across

market, continued are X adoption enjoying rapid accelerating and X seeing in We markets U.S. growth international launched. we're the our is Omnipod in type where

seeing Omnipod in We market growth across our the are type continued also offerings. X

life to of come. I global our world. for GO hard coming thank people for Omnipod with to we in and diabetes excited the engagement of the are catalysts entire drive about continue many years that simplify XXXX with functionality a work for unlock to We their the CGM-integrated market growth around iOS mission want as lot Insulet to our team millions

years. over the Interim Officer Treasurer. role and CFO Chief to Insulet to her has contributed value the a us. team close to member tenure for company long of to our key during and welcome has on her turn been Accounting and as Lauren, I want call our and I with X She congratulate and to is with Lauren has been Before her shareholders finance our significant

our execution I thrilled Lauren to are continued to turn have the call strategic in Lauren. priorities. With to role this support our will that, over We of

so CFO. It's honor as Jim. much, interim serve an Thanks to

in customer the new financial the global once another Omnipod And nice very markets Omnipod We U.S. achieved strategic a growth, of new demand launched and Jim in by quarter for are starts, starts fueled As delivered again X huge uptick seeing we customer we X. performance in shared, Insulin strong robust where progress. international

base, we end range. growth As the a XX% high in QX, result of our finishing our customer growing above revenue of delivered guidance

our for was currency year. basis, compared On Our and to foreign be and U.S. Omnipod QX This guidance basis our U.S. outperformance model increase ramp XX% Pods approximately growth growth includes from million, in tailwind dynamics net over related XX% an advantage, resulted was U.S. to was an this revenue, competitive driving volume for estimated range. Revenue and a the point Omnipod a Omnipod X a XX%. premium between of be by pharmacy represented in of revenue volume. Omnipod by QX Omnipod tailwind driven growth growing global and driven XXX Pharmacy X total of contribution our annuity-based we and to reported last U.S. pharmacy. and continues exceeded with channel is volume. for which DASH in $XX guidance. XX% what line remain the expected through in continues focused on in volume access we which channel, increased QX total

a Omnipod and new initial as benefit from our some customers whom As reminder, from since a plus orders X, the have quarter, refill kits in realized received net of pharmacies. first volume customers stocking recurring as we Omnipod retail well starter their in launch, to converting many

have Omnipod skipped the been as the an therefore X. as majority from net the expected, immaterial has order benefit switched we estimates of existing of volume customers already conversions been to normalizing QX, Omnipod those and customers Our who X our period. In in was

Going which Gross benefits increase X a customer by benefit included basis offset basis launch smaller Omnipod slightly over distributor of attrition million foreign degree, Growth lower These strong income over stable. device the as the above including declined of we $X.X new our Drug approximately associated from Delivery corrections estimated point in new adoption from starts. In in XXX Omnipod X incremental forecast we continue margin higher was impacted to revenue starts. of QX, International as continued U.K., script a partially costs XX%, notable drove and U.S. last our took points and to tailwind to were utilization a in announced forward, lower reported when to Omnipod $XX DASH partners. our X,XXX which charge and, prior lower last we by be we attrition year expect XX.X%, was a QX Omnipod below primarily driven was X we range currency orders. On the with year. a increased the up by our benefit remained drive due revenue medical customer was was X%, million slightly dynamics year. continued expectations. global which competition, a guidance due basis, AID from

was with a was margin margin larger XXX growth strong points our up in exceeded in this XX.X% of gross we support due expenses primarily continues driven improved production. Operating expectations become These expected our to our both, and line Adjusted manufacturing channel. increase pharmacy higher to margin. basis was year-over-year, offset the volume higher-than-anticipated of adjusted revenue trajectory. manufacturing total gross and to favorable increased as our $X.X to expectations of were in from portion exclude increases revenue. The and and in million adjusted invested partially a Excluding QX device medical XX.X% costs and by our premium gross year-over-year This as favorable correction were in to due adjustment XX.X%. EBITDA ramp manufacturing the margin our efficiency and year. U.S. were higher-than-expected growth expectations by business above costs production operating Both

invest our order innovation our pipeline Turning facility. $XXX in our financial sustainable build our million position to other on This cash flexibility $XXX the for gives full growth. under liquidity. the in We cash strong credit key in and us to foundation quarter and of the long-term areas to million organization available and ended with

to XXXX turning our outlook. Now

total of expectations For range revenue year, a XX%. revenue and to raising growth XX% range we company XX% are our XX% of to growth a to the full for to total Omnipod

revenue extent, channel. increasing Omnipod, Omnipod of strong the a adoption of is Omnipod growth Omnipod U.S. our our from lesser driven revenue a benefits stemming in XX% from DASH by primarily range to we and from other new from outlook as as increase to pharmacy well strong pay-as-you-go For and, are starts XX%. This the customer products model recurring conversions ongoing to continued X consecutive

channel the in Omnipod of QX a year X fourth tougher which of As year to contributing benefit, quarter quarter the year. XXXX. last of the in part first comparison prior accelerated It X-script was also stocking. of conversions The due customer pace was sales, a second half to reminder, in of large included this full included the the retail

of guidance Omnipod, we our International approximately a end raising and points. we basis to expect a growth. are now low XX% On reported estimate foreign favorable For of X% the impact basis, XXX range currency

We U.K. by be expect as benefit driven in Omnipod launches our growth and well Germany, AID from X ongoing partially DASH competitive Omnipod by adoption as offset the will the headwinds.

to we a nature of model, rate more the As reminder, given expect XXXX. Omnipod the contribute our to second meaningfully growth our annuity X of in half

of guidance XX% our For we to Drug Delivery, range XX% are reaffirming a decline.

margin. gross XXXX to Turning

expectations We The are a XX% range. this expect as of increase costs margin as is well to XX% higher-than-expected improved mix. to our raising guide revenue, favorable manufacturing gross of the range prior adjusted achieve including by to and midpoint driven from our

anticipate will carry remain in given that see outperformance. further XXXX. and headwinds to expansion we leveraging experienced to adjusted improvement during margin in our XXXX certain over operating to XXXX now in margin range We committed gross revenue investments and next margin our X% of year, margin XX% We the gross expect and we expect into Although beyond.

XXXX our to quarter guidance. revenue Turning fourth

XX% expect growth total and to of Omnipod company XX%. We total

last we continue growth Omnipod, expected our the and fuel strong our of growth, U.S. annuity sequential For market the benefits to growth our XX% in release to momentum new challenging full customers including comp year, of XX%. in with August dollar Even due start to QX. X of model expect revenue the Omnipod

a estimate impact approximately points. foreign For of X%. basis, XXX of we International exchange growth basis Omnipod, a X% reported to favorable we On expect

Drug million due of expect to to million orders. revenue $X and timing production Finally, be we Delivery approximately $X QX to

in across are for another strong momentum and XXXX. we our business, year sustained have We poised

given about February, we XXXX X While XXXX color in we provide we anticipate our the strong another in dollar growth formal see the will business. We large I on even realized now thinking year will ramp. provide XXXX from QX of in XXXX our volume the are how benefits significant in with momentum on some call guidance Omnipod

expect rate For starts our pace a mid-XX% as X its and new within pharmacy channel fueled model growth by of and U.S. we the access. well range, Omnipod as Omnipod, strong customer annuity

with the growth Germany. For of Omnipod second and the X the towards DASH Omnipod meaningful growth half U.K. year more our International, we expect from in recent continued and launches

We expect a where us second the somewhere in continued digits yet headwinds the in, half the to this of countries puts accelerating Omnipod partially not year X high do to offset digits. that All for the we growth. single to have year in range the high low single of with double digits

the For we to of through and high see lower a and quarter and the be further at Drug of decline, financial delivered the continued than we solid positioned this we performance, Insulet of for the decline another in end to end conclusion, beyond. year expect Delivery, expect XXXX. In we forecast, momentum

innovation, and customer the open in drive of and global poised and value revenue questions. well creation the operator, that, are on opportunity very of and magnitude we're growth invest continue As this are between, capitalize for for strong our far shareholders. With long-term for market base we to we Opportunities another few year call positioned please to growth.

question from from Our Robbie JPMorgan. comes [Operator Instructions] first Marcus

a Robbie. nice This is on quarter. on for Congrats really Rohan

tailwinds that providing about growth is as you we in developments to contribution exciting and think how each several integration, color targets targets related should international next what's of that launch preliminary year question and on are there the next outlined. my those you XXXX year more from on assumed deck those for well. the puts preliminary expansion. and iOS these takes But thanks just for outlined for CGM and between So And continued

that about very really early integration. Libre the And positioned. drive starts We're into in Rohan. the in the about we're limited Thanks, and We've both with also for excited well market, releases year continuing catalysts the and great really continuing obviously coming. continuing market GX and we to have momentum progress demand really got excited getting growth iOS customer new the strong about excited really

color. the haven't opens the a we So do it in one any the for want that. and they color Deb And us continued ask in across guide, so to necessarily that. the up catalyst. But think add of growth really wouldn't for think on other, our think I'll all to I growth drive we all over if us. And drive they really want for They're number do they important. potential board. we guided It's of to weigh lot terms we But Lauren

Sure. Thanks, Jim.

we But factored our be in Jim entering year. yes, And model, we're So meaningful have as of the beginning given in annuity in. not LMR a the them to expected just it's contribution. said,

question from comes Our next from Biegelsen Larry Wells Fargo.

Charles is This on for Larry.

then new First, you I record this quick on say starts I Did to right? I the follow-up. already. just patient nice quarter. ask, a And wanted were if And you I congrats got don't know said a worldwide? Did hear that

really were a record. not strong, starts New quite customer

-- cylinder. get new for customer blowout starts, but everything in quarters ever customer behind. the table our new all where kind it on we're was of our just so in hit of second, don't all a of us not to ranking time, we in second-highest every And want quarter coming was starts QX quarter the

record. So a the but happy with really not starts, new quite customer

I Okay. be just What a an Wondering if CFO. And wonder give line follow-up. able And time if update possible for give quick new could there? for you have search you you to might there. exactly a hope a announcement are you to looking on might an the

Sure, Charles.

in, blessed been We're chair. that and that to think on really with step really happy out have with the in talk for spec. of we're to We interim. And the long fun now a here written finance is in time. She's I we're us CFO so our don't a about looking characteristics great we're just the to the to for. market and want a have search. really Lauren all, conducting of of And a job somebody contributor to senior caliber We've search. the really team Lauren's the She's such First this company to and the job.

Lauren, because want get want very some the and including really right early person get can market to We as there. move really have role. we'll the strong, internal look candidates confident quickly as the We to in we who looks But we're we are to promising. at stability

Our from next question comes from Stephanie Bank America. Piazzola of

were a quarter. margins, strong improvement on the been quarter. and I to more have throughout wanted Congrats each the quarter about showing in good which really year ask

XXXX. So takes margins that But for appreciate revenue and on on be could helpful. you to any of share color next any color the would consider there's the Maybe you puts gave year, there? if

on that. Thanks, to Stephanie. I'll Lauren turn

ahead. ahead, Lauren. go Sorry, Go

providing little guidance today. for the very that the guidance gross we thrilled color, committed we to operating high expanding just And 'XX as are of margins we But we to XX% end our increased full range of well. also XX%. year we're increased our are that thrilled margin So We're not a margins. to

and very continue those, well. going forward we're as we would focused So on increasing that expect trend to

next comes from question Raymond Bedford Jayson Our James. from

This is for Jayson Jayson. on

physician Omnipod was can marketing way? as have greater that new a I'm any wondering growth And we user picture, just So quickly, in than you then big or changed if higher in assume with related the year-over-year your your growth? users type overall just U.S. X discussions follow-up, changed GLP strategy adoption? the

so It's well. been changed our marketing -- market. with GLP-X effective there. Omnipod no, all. haven't indicated learning going for is delivery. pilot in So yes at has X message are we're are GLP-Xs DASH insulin the time a And Omnipod GO and Omnipod we in some out -- X lot. The

we our changed haven't messaging. so And

me the and adapt continue obviously had learn second GLP-Xs. you there, Can messaging, of And to have we think your to lot we need to about remind we success. I if question we that will. our our But part change of of messaging, Jayson? a to haven't continue we

terms be year, type there's adoption. Type way I type at it added in just X faster feels would bless assume was that that of in look this of faster? year overall X like XQ a looked it it -- X strong Omnipod If last it's than assumption, grew great. versus that like number I to X Type Can just the If growth.

Lauren. that sure not Go jump I'm would I Go to ahead. split. ahead,

about it to grew going just was I same. say the

Patrick from from Morgan Wood comes question Our Stanley. next

as curious the mean, time of in longer picture, just guess, I the the around U.K., I'm about And to would through term, of double-digit prohibit big you're anything those from seeing you're how reaccelerating launch that how could not I growth is to you X line Omnipod region? what's just like Germany, there look. and sort that some returning 'XX, pushes markets thinking OUS slightly in

Yes, into in markets multiple so getting X excited Thanks. we're Omnipod about Europe.

wherever see growth As able I remarks, is a strong offer detailed any it launch leading really the And think going put we're market. well. answer said and going to we X. remarks, is out barriers very robust Omnipod as as in prepared question, of direct the we U.K. driving we Germany it's to gate. In -- be the your to to in don't where said I we're strong really launch in confident the prepared the we

access drive price evidence So we and conversations, we customers it's so for such real-world the value And X it's such that get for more we as a confident Omnipod a can easy creates. It drives can also get premium use. to great solution, we're great results.

ahead getting with And markets full international our speed systems so -- into in OX. we're all

Our next from question Baird. Johnson comes Jeff from

on sensor maybe Nice more bit if little pin Jim, a on you the down quarter. integration detail side. I could

a in that? And So Or and there and on far think the But OX. is Just LX you just like in integration, and U.S.? at LMRs, see OUS year, should U.S., obviously, out How And time updates it see we the updates the then in line the to in or depend internationally. we do about a is in X-month any that. check all? LX, I it's of launch? some on that generally, then go How front, it X-month tend to might about field, how to and think the I feedback LX what U.S. think guess, you once going early I on just notes, comes the year? LX? the my we all LX a road down a is gave integration could LMR back the Is full GX know in what LMR

we're We customer the experience And has Yes. we guidance providing RADIANT on good Europe. at this customer We're in about I'll trial. integration -- experience the point. integration RADIANT doing on reverse order. family Thanks, Libre which have been X RADIANT is the not of that terrific. in trial the Jeff. our with going Libre timing the do The go the sensors feel on additional for

trial that. And And be so in to have to a obviously, on bullish very we have we're with that system, integration. working

So for provide to any specific we're this on bullish Libre on not that, ready markets but we're moment. timing at

as great working and test exercises want sure way a don't We to. think make of LMR it's question, the -- we the question. hypotheses to system is LMR we it the On

We line don't on conditions a we a set time of it. on it. So put actually put

with that things, out to how we as we was LMR But with GX we into performs. see a the so the be weren't market to get in into product working confident get all with the you see. Obviously, integration going system it these expected. And as we'll LMR, we while wouldn't if see of have what

and that so quickly And we're about there GX really the we'll market. and to as as get integration excited we'll LMR move bringing out we can,

Our from next question Taylor comes Jefferies. Matt from

could get level. I you ask to. in I in do you're thoughts time, about my Obviously, market, proportion wanted success and the the into coming a Maybe broaden a some where level healthy type XX% to you that that? go having consistent even some fold over there have guess is, guess But the that good on future? are more with further X. indications question type you efforts your the also that increase today of as hopefully that to expect base being I once able you could prescriber the Xs to And additional offer

are both Thanks, questions. Matt. great Those

our right? so in expect on technology-based X X First and from penetration into we say to we're MDI so thing So type I'll is solution is X, offering customers onto the type bring therapy. are bringing market many those type drive to Pod that in a all not currently who market customers strong continue the to

a put shows bullish that X. Type X couple very been And on underpenetrated the massively continue. We're disease. progression million of that the that about need therapy. with insulin in portion of part intensive U.S. X will are we've diagnosed And type X our the underpenetrated therefore, then just it's market the market for growth type of therefore, and type pump up who million progress in then And X But people market. Pod insulin a type X.X for the they're now, who size investor so got -- on deck people times. therapy a bullish And Right numbers U.S. on and market this growing a care. MDI in XX-some-odd we're of is their we've for overall, through diabetes really X deck on our And -- intensive we the in as very to that. as type the basal very, therapy. and on there

we'll Type end So X. if than a therapy you think intensive type X. to continue type about penetrate X is -- larger market for actually insulin

market, on swing -- The will proportion proportion and do point, up. I for fronts. to customers the but to go in both your the will the of So as the numbers the use indication total number drive think, able will adoption up probably go get we're adoption

Sandler. question next from comes from Matthew Our Piper O'Brien

on quarter. for on Congrats Phil This the Matt. is

you for on we think conversions Just ratio ability Are MDI What from given has of you growth wait, does there. same ratio the things, seeing Also, pumpers? the being any kind of as ratio now that in key marched competitive could to MDI-to-conversion side slowdown the in in the Europe? look XX-XX volume to convert business about U.S. that like the if Jim, to the factors in XX-XX launch OUS provide of your

When talk QX back data QX a The Omnipod, components go enrolls apologize and I'll tell type into Phil. the of estimate -- a competitive weeds into the MDI customers, of weeds. about to -- for on of the from when sources of have customers of type conversion, hugely will The in Thanks, where are they're terms we different so us different X, usually. I was up, going voluntary coming doesn't we only where difference for just second, allow from. from look X mix coming if sources it's whether us that, customer that they including I

and there's what range not data information. capture, a on It's voluntary that little is estimation means those XXX% kind it's of of bit So an things.

compared X. on for really of than we it QX of from quarter, sustained that so only to surprise change. And In conversions been balance, not went competitive you of converting was We're that didn't really over that long we sustained was total the Omnipod that above the conversions the the and pleasant trends said, a launch for course in volume last different for thing we was even as The terms at we And a QX enough But little happy us that bit huge said of pumps range XX-XX. historical it competitive XX-XX. of of time and a was -- longer And launch little number looks kind probably change look for to different. all people of longer clear the with estimate us. said this a that, number number, XX-XX we've tubed thought. a quarter,

get could talk on we MDI this really about, from market the bring clear means -- us to it mix. And to to again, pumps. in on we're you -- AID bringing the on but We're back of for therapy is Pod market, into leader not taking to and XX-XX share continue it's X. the MDI broad customers the AID, So a surprise what category to we're still of tubed of market out base the clear leader installed Omnipod bringing in

haven't our field really And a promotional convert tubed people in for see harder out and so to we of matter, for any it making way the lot are us in in that's Omnipod pump we X, off compelling. their DASH, we move Omnipod experience But activity. data. see -- because not don't of anything reporting market, any is that And really the so

of more it. for, long than you're how see we answer a in-the-weeds kind So that's looking maybe but that's

fact, going question, market. of we're that -- U.K., in hospital. European And by is the market think side the I On different to different the it's hospital see in what by we see

conversion upgrading a more new start. are cases, from little year. hospital A X. some towards driven customers preference, by balance of physician tilting that bit of a bit the that instances, tilting on than is the customer driven in starts for as towards in more is new Omnipod by And budget and trust they're DASH some mix So little the with NHS hospitals Omnipod more

And so Germany, different see they'll little as we will a different look think a I we'll it I think I think countries. other look and in little into and -- get

a locks a in everybody into As Europe the reminder, contracting contract.

the a most channel. contract pharmacy in pump tubed on of convert DASH locked or easy a U.S., a you're into you're X. In markets, Omnipod So It's period the on from time. of we're for a Omnipod you're to European on the in to tubed pump, whether an

the for somebody so U.K., to at the to hospital of the example, it's upgrade And an discretion in Omnipod X.

in look know behavior market can that U.K. the -- that Omnipod so see will What do you our European for the by is demand And we pent-up markets is in X is little bit already a different Omnipod just the X results really and market. strong, market

Blair. William next Our Margaret question from from comes Kaczor

Omnipod I wanted to GO. about talk bit a little

you that the had on. I pull-through maybe sales early mentioned you're for think even family seeing whole Omnipod some in

XXXX maybe what guidance, that opportunity any at you're assuming sales any to patient and basis or you around there that pull-through then more the think of which of sneak relates you a as seeing Omnipod from about And commercial X? long-term a it? as benefit look however how detail account follow-up, is through, So from per are I'll direct that you

them Margaret. reverse I'll do order. in Thanks,

into the -- still We pilot, haven't pilot. out this planning a It's market anything formally guide even commercial we're release. put not GO Omnipod a so the of is limited and yet

we're as which I'm And we don't that because the is are Omnipod to we're GO as would GO, us it lot. that provided characterize way PCP tried it. we wanted, say, doing a Lauren GO get pleasant it's, of them pleased portfolio. I are we pilot, use would we a do as the what piloting offering these learning that only we product about of see kind for it recognize of into color And we that be the in the and guide. The include And ask ease quantify explain exactly surprise practices that patient haven't to about really so into But the Omnipod the the of broader or think they that -- target that, we the or talk not any Omnipod profile I happening. they they and anticipated we

conversation look so it like of like and care. testing we're things are out pilot mechanics So open And that the using is that. genuinely it's What Omnipod in How should the therapy primary what does things it pattern? us What's like? to that, figure up to is the we're -- the so And simple bag? what call what use many What's right? tells that target is it for in reps? patient the profiles the and

And been to patients so about channel. type think think primary in us really, I for really we continue from the have productive the pilot X learnings the but as to how approach as of it early days,

Our next Joanne question from from Citigroup. comes Wuensch

is for Anthony Joanne. This actually on

could here. tailwind. one number ramp whether a that it's the next just quarter this are $XX dynamics. Omnipod on confirm want guidance or I you with headwind? what to be then, to easy the a any quick providing million was a was I year, tailwind X And that the just confirm associated this want Just

Yes.

component So is million small $XX the is that. really phenomenon. a now And is script the of what's double that conversions different

immaterial. So it's really

our of on going So but normal continue, going forward, part customer we new forward really rate expect it's the double script starts. phenomenon to just growth

from Our next Canaccord William comes Plovanic from question Genuity.

great Bill. Caitlin Cronin a is on on Congrats quarter. for This

into new and year. into landscape some going for pumps tubed competition thinking in development and this bit kind market you about year kind are then of the also next forward? a more, been few patch How of potentially updates to and a entrants dig early like there's Just pumps it for U.S. the competitive little seems

as X what Omnipod pipelines position. competitive AID we Caitlin, X We're And best in is is Omnipod very competitor in confident think in with GX. our pipeline see the coming sensor as the nothing offering competitive on with -- we good market. GX

doesn't won't And so there competition. that -- and be it mean

activity there's of from some competitors competitors. earlier, out, said a see our I we As lot our around of promotional

So world. we that the see in out

it seen this really our at point. impact We haven't results

of it think I to always, customers is business. experience, is think trying competition and -- products, all first helps everybody It learn Now great better we're competition which develop helps what and do. I better all, for have

be going know catalysts XXXX. excited to so know competitors to try in very very, And to that's position and but have coming competitive about we our why competition. continue the confident we we're we're profile. We our And our so growth innovate, growth there's in

There's the to pumps that -- pump. pump leader viable a we're As on the competitor patch see really patch patch not there's patch horizon. we pump in companies,

another to position so on And and very, that market. bullish lead expect reason we're very continue our that's to the

from comes Leerink Kratky question next from Partners. Our Mike

impact pivotal the to X, increase Omnipod next the years? penetration opportunity thinking product trial main regarding so how ongoing could So are the for that other for that few within are over SECURE commercial expect the X this you remain how And underpenetrated? the drivers that patients what about type you insulin-intensive

Thanks for for about comments, the goal completed very And the we've SECURE as in our excited question. the We're prepared recruitment. trial. said I

minimum is patients has And designed so a XXX just means, but are to it patients, that to required. be trial be up number of that clear to what that

an patients. trial enrollment view. minimum the And that for And think of way about to the point we it the over that so from number the is crossed of hurdle derisks

enough the open. now is successfully still complete have Enrollment are to certain patients we So to trial.

you Once -- better rather gather trial. And the a patient trial the next the so had already derisked Omnipod more that protocol. XX-week on. results Omnipod the while last with type we'll to already. year. data, for a operationally is we'll patients market fewer. we X it's for this than then patients be that FDA. us in some Omnipod certain it enroll has get to we'll time. will little and type prepare is of have And in it's the they'll DASH. continue continue in, unlock clean DASH Type will then we'll to We'll data, And the need. enough can the So patients now leader in the powered the for in so always in And the for And promoting with the be huge results for indication protocol. use see a some hands because in X And submission X trial we've DASH an the the But X complete been type space. We're

DASH saw therapy, revenue. the of X. and And quarter, quarter-over-quarter, So a we're X really patients as if out Pod we're talking better actually clearly because, to little last you in well than in bit in of that's terms type did percent about growth physicians quarter driving type

not indication -- use, for We we X, not appeal does we high label have specifically people writing also X, type know type and very because even and it. though that are with it X Omnipod even yet people with we're AID AID though promoting for promote know X off it for cannot Omnipod has do an physicians

we once insulin GO PCP the which the come a with endocrinology X type reach a for will why DASH be or the from out because Omnipod either when we market, the use basal Omnipod success upstream our piloting you result so it channel, Omnipod can then they demand for pent-up SECURE the And offering, in as progress, an come X growth onto the on X indication Omnipod of extends X. And X it PCP the will offering. are will think and unlock what That's get Omnipod the also seamlessly take for things they Omnipod of together, is initiate we for in as in X patients the type those with us. That already successful trial, progress channel. they they pretty massive DASH in think type market, should we therapy growth obvious type channel X

from next Oppenheimer. comes from Steven Our Lichtman question

need prescriber base clearly Or grow? to endos. So the this you continues seeing from leverage prescriber street opportunities team? expand feet your meaningfully moving sort on to are your you mentioned past you're your high-volume current Do you earlier, of as base

And that Great would on question, Steve. things front. I X say

on that GO Omnipod is need one feet on the to street, get we reach many street out considering we expanding figure that's and of to pilot, first are commercial the the feet want. how part we the The

thing other leverage get a DTP. lot of we is of out The

what's lot a And physicians advertising them right are by don't And calling us is have our that often rep a the happening of now. writing reaches the way. for on so physicians, necessarily DTP

those maybe online So but a they for we ad, our often practices on Omnipod that don't and routine see or TV patients the go the ask media call product in into through with. have necessarily

as that consider you we're in on then feet So we leverage getting appropriate quarters. will the the street, over And way say, coming adding already. as

Our comes question from Pasquale from Chris Nephron. next

the data -- I thinking type approval? time OX just labeling. want are also already line of up of like spur actually on amount And you get to How interest. you that there's for seem about for would presentation it more opportunity. like the X follow sounds itself catalyst a perhaps then off-label even a because it FDA could interest be before And to the the data presentation fair also

Chris. questions, Great

a to easy of it's SECURE haven't fairly formal the out to we clearance do but timing, on First, time math. an FDA line announced on getting trial,

later to protocol, will patient the year, the think the end XX-week the I than in analyze a calendar data do filing. last be no probably a of

sure that. In couple data we'll terms say the And line to -- FDA on be filing or it's see happens those between and study. a for steps time now have a then, that there's things we'll expect can on think we terms year plus I 'XX are safe the file on the them. then in of for of with each So in of that what to next minus But for clearance. of in

GLP-X actually on did better we and than in we've And of We -- week. context in quarter explained that have also we the this reasons slides trial. data see last our on of of what updated out patients the data we news Omnipod that and the smallest trial GLP-Xs type our is that as that the feasibility referred that posted in do who we've in were X published GLP-Xs X that that feasibility on patients out to for not

body the insulin, to GLP-Xs required more so sensitive the And reduced dose. make and they

enrollees better we is minus, number, will in interesting. are along the current so of the outcome a just or that GLP-X. And a ends or of actually X either those anticipate combination trial plus And have the large on an which lines, SGLTX already with about a for patients, we that half, up

anticipate do on reporting scientific but to happen so may subsets That kind the able out on it filing, being of happen of report after, may some we as able And to trial. anticipate the -- FDA being we well may that during before happen it XXXX.

question from Our from comes Thibault BTIG. next Marie

on iOS Congrats the clearance.

GX Just all a the quick one see as we just When generation? with iOS here that. the on X integrated Omnipod might latest well,

Marie. the guided on haven't timing We that,

imagine that's to a us to. that urgent first. we'll can You get very do But matter first for things

the And X be which initially. a we'll GX And offering will an iOS, get systems into so we'll come will and with LMR get LMR together GX, after then that.

question Our Josh TD Cowen. Jennings comes next from from

fully endocrinologists? the prescriber then penetration strong into you the And Congratulations the X,XXX prescribers, X,XXX think base. expanding on can quarter. of on to chance through us on help another I U.S. Wanted to almost question prescriber practices? this Any the nurse follow better up guess, Steve's penetrated X,XXX? -- help additional those and PCPs? practitioners expansion Maybe to those they outside getting you're of some if where of Are you're just X,XXXX understand us endocrinology endocrinology. Are there,

prescribers data color But in Josh. I know or we don't of are perfect the -- to to very Deb That's if endo I'll have of question, than PAs Lauren I color endocrinologists. the writers Thanks, I'll then -- think provide as nurse we and/or have to the we well. are some extenders of practices turn I and that. mean some other practitioners see have. care other that specifics attached And practices. think with those well PCPs nonspecialist on penetrated we don't We that know your we're but

This all PCPs prescribing That's have, Deb. increasing from that from also HCPs. have seeing increases we No. of aspects. It's prescribers increasing from are becoming the We're seeing because color system great the is that Jim. it. we aware it's endos, that is we And are great we're what prescribers and seeing

look great. see increasing it data, we been over the last the and trend it's and quarter, So at we

we'll there. see where So it from goes

Our next Antalffy question UBS. from comes from Danielle

add the get majority own Omnipod indication. that you that's the servicing require really the is because a upon care high-prescribing to to do they're Or do you sales to going you of of ensure one physician And appropriately and type a X, X so around I a type executing my question on to you have Congrats strong base prescribing it I once is the that [ sort doing is lot, primary quarter. just what guess ask think X ] really question the to all population force? was that to do and physicians? enough here they get to

the main commercial understand channel. on to doing the of objectives what's want really than -- journey, in absolutely. our the that Primary primary type pilot. One of going is a We one really Omnipod that's Danielle. in are there. care a patient physicians kind better main X And right couple we're of things Thanks, person, of that's GO important care in now do we

it's true ringing into get pilot And as talk commercial the it's commercialize other practices, we'll see patient our course, are And the there full for allowed so our don't practices And to And is GO earlier, in approach a whole we're Omnipod in portfolio, portfolio. And -- them of indicated primary primary we a us present for not or develop of them, us Omnipod we're us much know out that to often so population primary GO better once several options. about how into to interested DASH. a of And Omnipod approach we're for very care. number for pilot, the find portfolio it finding there, an really X, about they're there. allowing I which said the of offering. But giving products. get including to target has promoting not opportunity

the sorry, media primary that see social tend direct-to-patient, -- or our advertising that does thing to that is other The and direct-to-consumer-type reach we into advertising DTP our channel.

physicians it. So medium often media that ask often patients their about see walk position see into and the and

We them So as to often need way agree I X we find channel. very with in where we're that well. type to really and they are And need where the are, you, primary service getting they patients. as leverage in

question come Matt Miksic will from last Our today from Barclays.

there needs. potentially basal maybe of entering with market market expectations if side patients the think so is portion of this, in clinical maybe terms Or just, of market the a around feel as attaching there us they that out-of-pocket is you with of into an sense Just update more could, sort move your I'm a of that seen a view addition, that a that size beyond insulin-intensive give potentially opportunity -- relationships speaking -- what the in the So with sort of the and this you've the far. But of you just is this to large on other of of is very particularly of thinking compared sort that interest being sort is portion as that of course, you on your opportunity? attractive that? to insulin-intensive

are on least at are X basal-only million therapy. There who U.S. Matt. the Thanks, Yes. patients in

trajectory million, only call X them to penetration in but that only X people U.S. million progresses, serve X such Omnipod say growth type people essentially Some that our because patients the in on basal-only disease to which helps to market a small the products Really our aim who with meaningful to million X so family when of their it those let's diabetes introduce inevitable. not have is insulin is therapy

their As offerings. different them. stay have conscious once-a-week and relationship we early, GO, include we're that a insulin, some benefits there. we of insulin disease with people There's and launch progresses, stay no been We market with asked will Omnipod in market MDI. And there's offerings people lot there's progresses. The there type with which before a a them which there's for of to for we We've we stay population be there therapy helping that a there's in market. that as of think that of us, companies the clear fact with room in a disease lot target there's looking the patient to then -- -- bring us, needles. is are with lot they We're therapy of and on their the

because very then don't of other a their an forget significant there's to like needles. And they take insulin. forget to their thing people They want So injectable don't therapy patients is the percentage do care. to take

that both in so we physicians, commercial and for we're and that's their out both pilot. our patients testing problems what solve these And we of think

will there in think of Omnipod help a we basal-only or on So DASH and them And them help therapy. us their many there early GO think patient market with journey, Omnipod Omnipod to for X. those up we we when And eventually, is get end importantly, we patient journey. their them meaningful for throughout patients can

helps the It's end. it a case. it's And patients early acquire And think if so basal much is the further of market. patient It's the both for theory in that's acquisition, that way, those us which us meaningful a customer early market cycle, you life to about upstream.

no Hollingshead further for remarks. I closing time. turn back at Jim like showing conference the would I'm to questions to this

There today. and to delivered their reached, other want in for have the get our to it's really there as them Insulet us out is launched the all and helping focus us excited a in us people help, exciting markets. joining which millions Germany a dedication market both reach good excited we're Omnipod leading diabetes. X, do Insulet driving the international the out to everybody, track intend in are lives of in for us. I and for today, Clearly X U.K. our We're thank type helped for everybody, and well now you, and we the and with Thank on in quarter type internationally Omnipod evening. clearly on development their because another on outstanding and of joining their for and to for of growth mission employees momentum with are to X all around that we've great track that world products, to have people deliver to U.S. the market have very that. Thanks, continue simplify we've family

a concludes conference. today's this and your and wonderful have Thank Ladies you day. gentlemen, participation, for

disconnect all may You